COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC:

Get the latest research information from NIH: Menu

Switching Osteoporosis Patients Currently on Oral Bisphosphonate to Zoledronic Acid

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details. Identifier: NCT00097812
Recruitment Status : Completed
First Posted : December 1, 2004
Last Update Posted : April 27, 2012
Information provided by (Responsible Party):
Novartis ( Novartis Pharmaceuticals )

Brief Summary:
The purpose of this study is to assess bone mineral density in patients switching from an oral bisphosphonate to zoledronic acid, compared to those staying on the oral bisphosphonate.

Condition or disease Intervention/treatment Phase
Osteoporosis Drug: zoledronic acid Phase 3

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Enrollment : 220 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Double
Primary Purpose: Treatment
Official Title: A Study to Assess the Safety, Tolerability, and Efficacy of Switching Patients Currently on Oral Bisphosphonate to Zoledronic Acid
Study Start Date : May 2004
Actual Primary Completion Date : December 2005
Actual Study Completion Date : December 2005

Resource links provided by the National Library of Medicine

MedlinePlus related topics: Osteoporosis

Primary Outcome Measures :
  1. To compare % change in Lumbar Spine BMD from Baseline to Month 12 in ZOL (annual i.v. infusion) vs Alendronate (weekly oral) osteoporotic post-menopausal women populations

Secondary Outcome Measures :
  1. To compare Biomarkers of bone turnover in the annual Zol i.v. and weekly alendronate populations
  2. To demonstrate continued bone remodeling by evaluation of bone biopsies in a subset of patients
  3. To assess patient preferences for annual i.v. therapy compared to weekly oral therapy through a patient questionnaire

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.

Layout table for eligibility information
Ages Eligible for Study:   45 Years to 79 Years   (Adult, Older Adult)
Sexes Eligible for Study:   Female
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Post-menopausal women between 45 and 79 years of age
  • Must be osteopenic/osteoporotic
  • Treatment with oral bisphosphonate for at least 1 year

Exclusion Criteria:

  • Any woman of child bearing potential
  • Treatment with other bone active agents

Other protocol-defined inclusion/exclusion criteria may apply.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its identifier (NCT number): NCT00097812

Layout table for location information
United States, California
The Permanente Medical Group
Santa Rosa, California, United States, 95403
United States, Colorado
Colorado Center for Bone Research
Lakewood, Colorado, United States, 80227
United States, Florida
Florida Medical Research Institute
Gainsville, Florida, United States, 32605
Radiant Research
Stuart, Florida, United States, 34996
United States, Kansas
University of Kansas School of Medicine/ Division of Endocrinology
Kansas City, Kansas, United States, 66160
United States, Massachusetts
Clinical Pharmacology Study Group
Worcester, Massachusetts, United States, 01610
United States, Nebraska
Arthritis Center of Nebraska
Lincoln, Nebraska, United States, 68516
Creighton University Osteoporosis Research Center
Omaha, Nebraska, United States, 68131
United States, Oregon
Oregon Osteoporosis Center
Portland, Oregon, United States, 97213
United States, Pennsylvania
University of Pittsburgh
Pittsburgh, Pennsylvania, United States, 15213
Radiant Research
Wyomissing, Pennsylvania, United States, 19610
United States, Washington
Puget Sound Osteoporosis Center
Seattle, Washington, United States, 98144
Nuernberg, Germany
Sponsors and Collaborators
Novartis Pharmaceuticals
Layout table for additonal information
Responsible Party: Novartis Pharmaceuticals Identifier: NCT00097812    
Other Study ID Numbers: CZOL446H2313
First Posted: December 1, 2004    Key Record Dates
Last Update Posted: April 27, 2012
Last Verified: April 2012
Keywords provided by Novartis ( Novartis Pharmaceuticals ):
osteoporosis, osteopenia, post-menopausal, zoledronic acid
Additional relevant MeSH terms:
Layout table for MeSH terms
Bone Diseases, Metabolic
Bone Diseases
Musculoskeletal Diseases
Metabolic Diseases
Zoledronic Acid
Bone Density Conservation Agents
Physiological Effects of Drugs